Arbutus Biopharma
ABUS
166 hedge funds and large institutions have $536M invested in Arbutus Biopharma in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 54 reducing their positions, and 16 closing their positions.
284% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $3.26M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
47% more capital invested
Capital invested by funds: $365M → $536M (+$171M)
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
2% more funds holding
Funds holding: 162 → 166 (+4)
0.03% less ownership
Funds ownership: 61.67% → 61.64% (-0.03%)
6% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.96M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.15M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.01M |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.87M |
| 5 |
Morgan Stanley
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$3.31M |
| 2 |
Goldman Sachs
New York
|
-$3.18M |
| 3 |
BCP
BlackBarn Capital Partners
New York
|
-$2.22M |
| 4 |
SCM
Saba Capital Management
New York
|
-$2.14M |
| 5 |
FC
Foursixthree Capital
New York
|
-$2.12M |
ABUS Hedge Fund Activity: Q3 2025 in Review
166 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2025, worth a combined $536M — up 47% from $365M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ABUS positions and 16 closed out — a net gain of 5 holders — while 51 added to existing stakes and 54 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $8.96M. The largest seller was UBS AM, exiting entirely with an estimated $3.31M sold.
- 166 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2025, up from 162 in Q2 2025.
- Funds reported $536M of Arbutus Biopharma stock for Q3 2025, up 47% quarter-over-quarter.
- 21 funds opened new Arbutus Biopharma positions in Q3 2025 and 16 closed out, a net change of +5 holders.
- The largest Arbutus Biopharma buyer in Q3 2025 was Adage Capital Partners, an estimated $8.96M added.
- The largest Arbutus Biopharma seller in Q3 2025 was UBS AM, an estimated $3.31M sold.
Based on aggregated 13F filings for Q3 2025.